Virax Biolabs Group Limited (VRAX) Revenue History
Annual and quarterly revenue from 2020 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
VRAX Revenue Analysis (2020–2025)
As of March 5, 2026, Virax Biolabs Group Limited (VRAX) generated trailing twelve-month (TTM) revenue of $162,750, reflecting significant decline in growth of -98.3% year-over-year. The most recent quarter (Q4 2025) recorded $1,378 in revenue, down 72.2% sequentially.
Looking at the longer-term picture, VRAX's 5-year compound annual growth rate (CAGR) stands at -42.4%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $156,419 in 2024.
When compared to Healthcare sector peers including CAI (+144.9% YoY), VCYT (+16.0% YoY), and ADPT (+42.6% YoY), VRAX has underperformed the peer group in terms of revenue growth. Compare VRAX vs CAI →
Peer Comparison
Compare VRAX's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VRAXCurrent | $162,750 | -98.3% | -42.4% | -97344.8% | |
 CAI | $812M | +144.9% | +14.3% | 5.6% | |
 VCYT | $517M | +16.0% | +34.5% | 11.2% | |
 ADPT | $179M | +42.6% | +16.0% | -90.8% | |
 CDIO | $34,890 | -55.8% | - | -23977.9% | |
 SEER | $14M | +14.5% | +160.6% | -717.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $6K | -96.0% | $-53,067 | -838.2% | $-6,162,897 | -97344.8% |
| 2024 | $156K | +1727.1% | $51K | 32.3% | $-6,496,473 | -4153.3% |
| 2023 | $9K | - | $-1,365 | -15.9% | $-5,732,760 | -66963.7% |
| 2022 | $0 | -100.0% | $0 | - | $-1,733,680 | - |
| 2021 | $124K | +24.0% | $-9,434 | -7.6% | $-644,540 | -520.5% |
| 2020 | $100K | - | $46K | 45.8% | $-651,244 | -652.1% |
See VRAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VRAX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VRAX vs LLY
See how VRAX stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
Is VRAX's revenue growth accelerating or slowing?
VRAX revenue declined -98.3% year-over-year, contrasting with the 5-year CAGR of -42.4%. TTM revenue fell to $162750.00. This reverses the prior growth trend.
What is VRAX's long-term revenue growth rate?
Virax Biolabs Group Limited's 5-year revenue CAGR of -42.4% reflects the variable expansion pattern. Current YoY growth of -98.3% is below this long-term average.
How is VRAX's revenue distributed by segment?
VRAX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2025 are available for download. Segment mix reveals concentration and diversification trends.